Serious risks
Call your healthcare provider right away
Veylora may cause serious infections, liver injury, changes in blood cell counts, and blood clots. Some events may require treatment interruption or permanent discontinuation.
Serious infections
Veylora can affect the immune system and may lower the ability to fight infections. Bacterial, viral, fungal, and opportunistic infections have occurred. Do not start Veylora during an active serious infection. Tell your healthcare provider about fever, chills, sweating, cough, shortness of breath, painful urination, diarrhea, skin sores, or unusual tiredness.
Testing for tuberculosis and viral hepatitis should occur before treatment. Patients with latent tuberculosis should complete appropriate therapy as directed.
Liver problems
Increased ALT and AST levels occurred in clinical studies. Seek medical advice for yellow skin or eyes, dark urine, pale stool, persistent nausea or vomiting, upper-right abdominal pain, loss of appetite, or unusual fatigue.
Blood clots
Deep vein thrombosis and pulmonary embolism were reported. Get emergency medical help for sudden shortness of breath, chest pain that worsens when breathing, coughing blood, rapid heartbeat, or swelling, warmth, redness, or pain in an arm or leg.
Who should not take Veylora?
- People with an active serious infection
- People with a known severe hypersensitivity to naveritinib or another tablet ingredient
- People with severe hepatic impairment
Pregnancy, contraception, and breastfeeding
Based on its mechanism and fictional animal studies, Veylora may cause fetal harm. Patients who could become pregnant should use effective contraception during treatment and for 4 weeks after the final dose. Do not breastfeed during treatment and for 1 week after the final dose.
Common side effects
| Adverse reaction | Veylora (n=94) | Placebo (n=92) |
|---|---|---|
| Upper respiratory infection | 18% | 9% |
| Headache | 15% | 11% |
| Nausea | 13% | 6% |
| Increased liver enzymes | 11% | 3% |
| Diarrhea | 10% | 7% |
| Fatigue | 9% | 5% |
These are not all possible side effects. Contact your healthcare provider for medical advice. In a real product context, suspected adverse reactions would be reported to FDA at 1-800-FDA-1088 or through the manufacturer.
Ingredients
Active ingredient: naveritinib. Inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, iron oxide yellow, and triacetin.
Prepare for a treatment conversation
Bring a complete medicine list and discuss your history of infection, liver problems, blood clots, pregnancy, and vaccinations.
Review dosing and monitoring →